Breaking Down Autek China Inc. Financial Health: Key Insights for Investors

Autek China's recent financial snapshot forces investors to weigh resilience against softening demand: revenue slipped to 870 million yuan in H1 2025 (‑1.42% YoY) after 2024 full‑year sales of 1.81 billion yuan (+4.40% YoY), while profitability softened with 2024 net income at 572.23 million yuan (‑14.16% YoY), net profit margin down to 32% from 38% and EPS falling to 0.64 yuan; H1 2025 shows a core gross margin of 34.2% (‑6.9pp) but an operating margin of 40.55% and ROE of 10.19%, revenue per employee of 507,099 yuan, and a conservative balance sheet highlighted by a market cap of 13.28 billion yuan, debt‑to‑equity of 0.05, total debt of 291.47 million yuan against cash of 2.07 billion yuan (net cash of 1.77 billion yuan); liquidity and solvency look robust with a current ratio of 5.10, quick ratio 3.18, interest coverage 45.10, operating cash flow of 669.38 million yuan and free cash flow of 536.03 million yuan (Altman Z‑Score 11.18), yet valuation signals caution-trailing P/E 26.93, forward P/E 21.97, P/S 7.31, PEG 8.78 and EV/EBITDA 15.75-while strategic moves (acquisition of Jiangsu Duozhi, 490+ optical service terminals, new high‑oxygen lenses and expansion into myopia management) offer growth avenues amid near‑term margin pressure from shifting product mix and competition; dive into the full analysis for the detailed metrics investors need.

Autek China Inc. (300595.SZ) - Revenue Analysis

Autek China Inc. reported mixed topline results across 2024 and H1 2025, reflecting modest annual growth followed by a slight contraction in the first half of 2025. Key drivers include its direct-sales model for prescription medical devices, workforce productivity, competitive pressures, and shifting consumer spending patterns.

• 2024 annual revenue: 1.81 billion yuan (up 4.40% year-on-year).
• H1 2025 revenue: 870 million yuan (down 1.42% year-on-year).
• Revenue per employee: 507,099 yuan, indicating relatively high labor productivity for the sector.

Revenue composition and model:

• Primary channels: direct sales of high-value, prescription-based medical products to hospitals, clinics, and optical retailers.
• Customer mix emphasizes institutional purchasers with longer sales cycles but higher average order values.
• Pricing and margin sensitivity tied to product mix and contract scale with healthcare institutions.

Drivers behind the H1 2025 decline and outlook:

• Reduced consumer spending and intensified competition compressed demand and slowed ordering cadence in H1 2025.
• Inventory and tender timing effects with institutional buyers can create uneven quarterly revenue recognition.
• Management expects a rebound in H2 2025 supported by newly launched product lines and renewed tender wins.

Implications for investors:

• Stable annual growth in 2024 suggests resilient core demand; H1 2025 decline is modest and potentially cyclical.
• High revenue per employee supports operational efficiency, but sustaining top-line growth will depend on product innovation and market share defense.
• Watch H2 2025 quarterly revenue and order backlog disclosures for confirmation of the anticipated recovery.

For additional background on the company's strategy, ownership and how it generates revenue, see: Autek China Inc.: History, Ownership, Mission, How It Works & Makes Money

Autek China Inc. (300595.SZ) - Profitability Metrics

• Net income (2024): 572.23 million yuan, down 14.16% vs. 2023.
• Net profit margin (2024): 32.0% (2023: 38.0%), contraction due to rising costs.
• Earnings per share (EPS, 2024): 0.64 yuan (2023: 0.75 yuan).
• Gross margin - core business (H1 2025): 34.2%, down 6.9 percentage points YoY.
• Operating margin (H1 2025): 40.55%, indicating continued operational leverage.
• Return on equity (ROE): 10.19%.

• Investors should weigh the decline in net margin and EPS against high operating margins in H1 2025 when assessing profitability resilience.
• For broader context on Autek China's background, structure and business model, see: Autek China Inc.: History, Ownership, Mission, How It Works & Makes Money

Autek China Inc. (300595.SZ) - Debt vs. Equity Structure

• Market capitalization: 13.28 billion yuan.
• Total debt: 291.47 million yuan.
• Cash and cash equivalents: 2.07 billion yuan.
• Net cash position (Cash - Debt): 1.78 billion yuan (rounded from 1.773 billion).
• Debt-to-equity ratio: 0.05, indicating minimal financial leverage.
• Enterprise value (EV): 11.99 billion yuan, reflecting market value adjusted for net debt.

• Financial flexibility: strong cash buffer supports capex, R&D, dividends, or strategic M&A.
• Risk profile: low debt reduces interest expense sensitivity and refinancing risk.
• Valuation note: EV below market cap reflects the company's net cash advantage versus peers with higher leverage.

Autek China Inc. (300595.SZ) - Liquidity and Solvency

Autek China Inc. (300595.SZ) presents a robust liquidity and solvency profile powered by strong current and quick ratios, substantial operating cash flow, and a very high Altman Z-Score. These metrics collectively indicate comfortable short-term coverage of obligations and a low probability of financial distress.

• Current ratio: 5.10 - ample short-term asset coverage of current liabilities.
• Quick ratio: 3.18 - liquid assets (ex-cash-absorbing inventory) comfortably cover immediate liabilities.
• Interest coverage ratio: 45.10 - operating earnings greatly exceed interest expense, reducing refinancing risk.
• Operating cash flow (TTM): ¥669.38 million - strong cash generation from core operations.
• Capital expenditures (TTM): ¥133.35 million - modest reinvestment relative to cash flow.
• Free cash flow (TTM): ¥536.03 million - substantial cash left after capex for deleveraging, dividends, or investments.
• Altman Z-Score: 11.18 - indicates a very low risk of bankruptcy under standard interpretation.

The combination of high liquidity ratios, significant free cash flow, and an Altman Z-Score well above distress thresholds suggests Autek China Inc. has the financial flexibility to meet both near-term obligations and longer-term commitments, while maintaining capacity for discretionary cash uses. For additional investor context, see Exploring Autek China Inc. Investor Profile: Who's Buying and Why?

Autek China Inc. (300595.SZ) - Valuation Analysis

• Trailing P/E: 26.93 - implies investors pay ~27x last twelve months' earnings.
• Forward P/E: 21.97 - market expects earnings to improve, reducing the multiple versus trailing.
• P/S: 7.31 - the stock is valued at over seven times annual sales, indicating strong revenue multiple pricing.
• P/B: 2.44 - equity valued at ~2.4x book, a moderate premium to net assets.
• PEG: 8.78 - very high relative to 1.0 benchmark, suggesting price outpaces earnings growth expectations.
• EV/EBITDA: 15.75 - reflects an enterprise-level valuation that is elevated versus many industrial/tech peers.

• Relative positioning: these multiples collectively suggest Autek China is trading at a premium to typical industry averages; investors should reconcile this premium with company-specific growth prospects, margin sustainability, and capex needs.
• Risk signal: the very high PEG (8.78) is a warning that projected growth may not sufficiently justify the current price unless the firm delivers materially higher earnings growth.
• Value drivers to monitor: ongoing revenue growth, margin expansion to justify P/S and EV/EBITDA, and realization of forecasted earnings that support the forward P/E.

Autek China Inc. (300595.SZ) - Risk Factors

• Revenue decline H1 2025: Management attributes the drop to reduced consumer spending and intensified competition in both prescription and myopia-control segments.
• Gross margin pressure: Core business gross margin in H1 2025 was 34.2%, down 6.9 percentage points year‑on‑year, squeezing operating leverage.
• Net profit margin compression: Net profit margin attributable to shareholders for H1 2025 was 28.7%, a decline of 11.7 percentage points year‑on‑year.
• Product mix risk: The rigid contact lens segment faces headwinds as lower‑priced myopia prevention products gain market share, reducing share of higher‑margin rigid lenses.
• 2024 profit growth slowdown: The decline in profit growth in 2024 is mainly due to a lower proportion of sales from higher‑margin rigid contact lenses versus softer-margin products.
• Short‑term profitability impact from investments: Ongoing investments into new product lines and optometry service terminals may depress near‑term margins and cash flow until scale and service adoption are achieved.
• Market and competitive risks: Increased price competition, channel pressure, and consumer sensitivity to discretionary spending can further compress revenue and margins.
• Execution and adoption risk: New product and service initiatives require successful commercialization and partner/channel execution to offset declining legacy margins.

• Investor considerations:
  • Monitor product mix trends - restoration of rigid lens share could materially improve margins.
  • Track adoption and revenue contribution from new product lines and optometry service terminals to assess ROI and margin recovery timeline.
  • Watch cash flow and working capital given potential short‑term margin compression from investments.

Autek China Inc. (300595.SZ) Growth Opportunities

• New-generation contact lenses: launched silicone‑hydrogel lenses with high oxygen permeability (Dk/t ≈ 80-120), which can address comfort and health concerns and increase market competitiveness.
• Acquisition of Jiangsu Duozhi: strategic move to enter the colored contact lens market and leverage Duozhi's established sales channels and distribution network.
• Retail & service footprint: over 490 optical service terminals established by the end of 2024, providing a direct platform to cross‑sell products and expand medical services.
• Myopia management focus: positioning in specialty myopia-control solutions (orthokeratology, multifocal soft lenses, atropine adjuncts), a segment with secular demand driven by rising prevalence-China myopia market CAGR estimated ~8-10%.
• Community-based professional optical services: developing localized professional networks to improve customer retention and recurring revenue opportunities.
• Specialty products & promotions: introducing premium specialty SKUs and targeted promotional policies to stabilize revenues in the traditionally rigid contact lens segment.

• Revenue drivers and assumptions: higher-margin specialty lenses and medical services (myopia management, orthokeratology fittings) expected to raise blended gross margin by 3-6 percentage points if adoption reaches targeted penetration.
• Distribution leverage: converting a portion of 490+ terminals into paid myopia-management clinics and fitting centers could increase same-store revenue per terminal by an estimated 20-35% over 24 months.
• Cross-sell potential through Jiangsu Duozhi: colored lens SKUs typically carry 10-25% higher ASPs (average selling prices) versus basic disposables-supporting margin expansion.